In the trust's annual report for 2023, managers Tim Creed and Harry Raikes set out the progress made towards rebalancing the portfolio to ensure the «appropriate» liquidity to execute the share repurchase programme announced in September 2023 and «support the portfolio». To accomplish this, the managers reduced INOV's holding in Oxford Nanopore, one of the trust's legacy holdings dating back to Neil Woodford's tenure as fund manager of the former Woodford Patient Capital trust. As of 31 December 2022, Oxford Nanopore comprised 23.3% of the trust's total equity holdings. By the end of ...
To continue reading this article...
Join now
Login
Read more on investmentweek.co.uk